Final results of the IKF-AIO-Moonlight trial

FOLFOX plus nivolumab has become the standard-of-care for first-line therapy of patients with oesophagogastric adenocarcinomas [1]. In this context, the phase 2 IKF-AIO-Moonlight trial (NCT03647969) investigated treatment regimens of dual checkpoint inhibition (FOLFOX + nivolumab/ipilimumab) and triplet chemotherapy (FLOT + nivolumab). Presenting the final results, Dr Sylvie Lorenzen (Rechts der Isar Hospital, Germany) concluded that: “The addition of nivolumab/ipilimumab to FOLFOX did not increase activity but did increase toxicity rates compared with FOLFOX monotherapy. FOLFOX plus nivolumab/ipilimumab administered in parallel was more effective than FOLFOX induction followed by nivolumab/ipilimumab. FLOT plus nivolumab was feasible and seemed to be associated with improved efficacy.”

1. Janjigian YY, et al. Lancet 2021;398:27-40.
2. Lorenzen S, et al. Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial. Abstract LBA59, ESMO Congress 2024, 13–17 September, Barcelona, Spain.

 

Copyright ©2024 Medicom Medical Publishers



Posted on 4 November 20244 November 2024